Genmab's recently approved therapy for cervical cancer that has come back or spread, Tivdak, has been turned down for NHS use in initial guidance from reimbursement authority NICE. Tivdak (tisotumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results